WallStreetZenWallStreetZen

NASDAQ: FULC
Fulcrum Therapeutics Inc Stock Ownership - Who owns Fulcrum Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Fulcrum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Greg TourangeauPrincipal Accounting Officer2025-05-08498$5.06
$2.52kSell

1 of 1

FULC insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FULC insiders and whales buy or sell their stock.

FULC Shareholders

What type of owners hold Fulcrum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP31.84%17,229,099$144.21MInsider
Ra Capital Management LP18.90%10,229,099$85.62MInstitution
Mark J. Levin11.17%6,046,425$50.61MInsider
Tcg Crossover Management LLC9.70%5,250,000$43.94MInstitution
Suvretta Capital Management LLC9.39%5,082,900$42.54MInstitution
Adage Capital Partners GP LLC8.48%4,589,000$38.41MInstitution
Blackrock Inc8.09%4,379,023$36.65MInstitution
Nantahala Capital Management LLC7.92%4,288,299$35.89MInstitution
Vanguard Group Inc5.81%3,146,443$26.34MInstitution
Third Rock Ventures III LP4.62%2,499,343$20.92MInsider

1 of 3

FULC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FULC62.17%37.83%Net Selling
NMRA25.51%74.49%Net BuyingNet Buying
BCYC57.89%42.11%Net BuyingNet Selling
CGEM56.12%43.88%Net BuyingNet Buying
LCTX39.04%60.96%Net Buying
View Top Biotech Stocks

Fulcrum Therapeutics Stock Ownership FAQ

Who owns Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ: FULC) is owned by 100.52% institutional shareholders, 61.18% Fulcrum Therapeutics insiders, and 0.00% retail investors. Ra Capital Management LP is the largest individual Fulcrum Therapeutics shareholder, owning 17.23M shares representing 31.84% of the company. Ra Capital Management LP's Fulcrum Therapeutics shares are currently valued at $135.59M.

If you're new to stock investing, here's how to buy Fulcrum Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.